Search clinical trials for: L9LS (VRC-MALMAB0114-00-AB)

Total 107 results

National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); University of Washington; Harvard School... and other collaborators

Active, not recruiting

Anti-malaria MAb in Malian Children (L9LS)

Malaria | Plasmodium Falciparum Infection

Mali
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); University of Washington; Vaccine Research... and other collaborators

Completed

L9LS MAb in Malian Adults

Malaria | Plasmodium Falciparum Infection

Mali
National Institute of Allergy and Infectious Diseases...

Completed

Trial to Evaluate L9LS in Healthy Adults (VRC 614)

Malaria

United States
National Institute of Allergy and Infectious Diseases...
University of Washington; Malaria Research and Training Center, Bamako, Mali; Harvard School of Public Health (HSPH)

Completed

Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali

Malaria | Plasmodium Falciparum Infection

Mali
National Institute of Allergy and Infectious Diseases...

Completed

Trial to Evaluate CIS43LS in Healthy Adults

Malaria

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

HIV Infections

United States, Puerto Rico, Zimbabwe, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

Monoclonal Antibody, Human | HIV Antibodies | Neutralizing Antibody | Prevention of HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

Healthy Adult Immune Response

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

HIV-1

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants (VRC07-523LS)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

HIV Infection | Monoclonal Antibody, Human | HIV Antibodies | VRC01 Monoclonal Antibody | Neutralizing Antibody

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults

HIV

United States
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Acute HIV Infection

United States, Brazil, Peru
National Institute of Allergy and Infectious Diseases...

Completed

VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption

HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

HIV Prevention

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults (VRC 611)

HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

HIV Infections

United States, Switzerland
National Institute of Allergy and Infectious Diseases...

Completed

Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (VRC 609)

HIV Antibodies

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

HIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal Antibody

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Centers for Disease Control and Prevention; International AIDS Vaccine Initiative and other collaborators

Withdrawn

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

HIV Infections
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection

HIV Infections

Thailand
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
United States Department of Defense

Completed

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

HIV Infections

Uganda, Kenya, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women

HIV Infections

South Africa, Zimbabwe, Malawi, Botswana, Kenya, Mozambique, Tanzania
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

HIV Infections

United States, Peru, Brazil, Switzerland
University of California, San Francisco
amfAR, The Foundation for AIDS Research

Recruiting

PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)

HIV-1-infection

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions

HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

Healthy Adult Immune Responses to Vaccine

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients

HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

HIV Infections

Rwanda, Kenya
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

HIV Infections

United States, Peru
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

Healthy Adult Immune Responses to Vaccine

United States
National Institute of Allergy and Infectious Diseases...

Completed

"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents (DNA)

RNA Virus Infections | Virus Diseases | Flavivirus Infections | Flaviviridae Infections | Zika Virus Infection | Zika Virus | Flaviviral Diseases

United States, Puerto Rico, Mexico, Brazil, Colombia, Costa Rica, Ecuador, Panama, Peru
National Institute of Allergy and Infectious Diseases...

Completed

HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers

HIV Infections | Healthy

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

Chikungunya Virus Infection

Dominican Republic, Puerto Rico, Guadeloupe, Haiti, Martinique
National Institute of Allergy and Infectious Diseases...

Completed

Phase 1 Safety Study of Two Experimental HIV Vaccines

HIV Infections | HIV-1 | AIDS Vaccines

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to Two Experimental HIV Vaccines in Healthy Adults

Innate Immunity | HIV Negative | Adaptive Immunity

United States
National Institute of Allergy and Infectious Diseases...

Completed

Ebola and Marburg Virus Vaccines

Ebola Virus Disease | Ebola Vaccines | Marburg Virus Disease | Marburgvirus | Ebolavirus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
International AIDS Vaccine Initiative

Withdrawn

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults

HIV Infections
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC; US Military HIV Research Program

Completed

Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

Hemorrhagic Fever, Ebola

Uganda
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults

Healthy Adult Immune Responses to Vaccine

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

HIV Infections

United States

Search clinical trials for: L9LS (VRC-MALMAB0114-00-AB)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations